TRCT
XTLB

Tower Research Capital (TRC)’s XTL Biopharmaceuticals XTLB Stock Holding History

Tower Research Capital (TRC)’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-244
Closed -$588 – 5714
2026
Q1 		$588 Buy
+244
New +$774 ﹤0.01% 4834
2022
Q1 		– Sell
-38
Closed – – 6604
2021
Q4 		$0 Buy
+38
New +$526 ﹤0.01% 6628
2016
Q4 		– Sell
-30
Closed -$1K – 4477
2016
Q3 		$1K Hold
30
– – ﹤0.01% 3386
2016
Q2 		$1K Sell
30
-10
-25% -$215 ﹤0.01% 4229
2016
Q1 		$1K Buy
40
+35
+700% +$898 ﹤0.01% 3811
2015
Q4 		$0 Sell
5
-15
-75% -$504 ﹤0.01% 5125
2015
Q3 		$1K Buy
+20
New +$737 ﹤0.01% 3694
2015
Q1 		– Sell
-51
Closed -$2K – 5008
2014
Q4 		$2K Sell
51
-6
-11% -$261 ﹤0.01% 3401
2014
Q3 		$2K Buy
57
+20
+54% +$1.04K ﹤0.01% 3887
2014
Q2 		$2K Buy
37
+12
+48% +$794 ﹤0.01% 3471
2014
Q1 		$2K Buy
25
+7
+39% +$506 ﹤0.01% 3924
2013
Q4 		$1K Buy
+18
New +$1.47K ﹤0.01% 4267

Other funds holding XTLB

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s XTLB Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of XTL Biopharmaceuticals (XTLB) in Q2 2026, closing a stake of 244 shares — an estimated $588 sold.

Tower Research Capital (TRC) first reported a position in XTLB in Q4 2013 and held it in 12 quarters. The position peaked at $2K in Q4 2014. 3 funds tracked by Wall St. Rank hold XTLB as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining XTL Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 244 XTL Biopharmaceuticals shares in Q2 2026, an estimated $588.
  • Tower Research Capital (TRC) first reported a position in XTL Biopharmaceuticals in Q4 2013 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s XTL Biopharmaceuticals position peaked at $2K in Q4 2014.
  • 3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.